Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- No conflict of interest
- Content
- History of (chemo)therapy of tuberculosis
- Some serious attempts before antibiotics
- The aims
- The problems
- How to evaluate the efficacy
- An expert opinion in 1946!
- The main problem
- Chronology of drug discovery
- Historical trials
- Streptomycin: first BMRC controlled trial
- The search for the best combination and duration
- The Madras trials (from 1966)
- The East African / BMRC trials
- The proof of the pudding is in the relapse rate
- Trials with different durations of therapy: East & Central Africa
- Trials with different durations of therapy: Hong Kong
- Trials with different durations of therapy: Madras
- Trials with different durations of therapy: optimal regimen
- Trials of shorter regimens: Johnson
- Trials of shorter regimens: Gillespie
- WHO guidelines
- The current standard regimen (since 1976)
- WHO current recommendations 2017: drug susceptible pulmonary TB and duration
- WHO current recommendation 2017: drug susceptible pulmonary TB and dosage
- The main anti-TB drugs: isoniazid (INH, H)
- Rifampicin (RMP, R)
- Pyrazinamide (PZA, Z)
- Ethambutol (EMB, E)
- Quinolones
- Injectables
- Linezolid (LNZ, L)
- Bedaquiline (TMC207, BDQ, B)
- Delamanid (OPC-67683, DLM, D)
- Pretomanid (PA 824, Pa)
- Special situations
- Treatment of CNS TB: regimen
- Treatment of CNS TB: a study
- WHO current recommendations 2017: CNS and pericarditis
- Treatment for TB in children
- Treatment of TB during pregnancy
- WHO current recommendations 2017: PLHIV
- WHO current recommendations 2017: ART
- The drug level and therapeutic margin
- Treatment of TB: the problem of adherence
- Factors affecting adherence to treatment
- WHO current recommendations 2017: patient support
- Supervision of TB treatment (Bénin)
- Treatment of TB: some other options
- Can we increase the local activity of anti-TB drugs?
- Aerosol formulation of anti-TB drugs
- Antituberculosis drugs by inhalation
- Adjuvant therapy for tuberculosis
- The ideal treatment and the current situation
- Conclusions
- TB drugs and palatability
- Thank you!
Topics Covered
- History of chemotherapy
- Current first-line drugs and mechanisms of action
- Main second-line drugs
- Standard regimens
- Special situations: pregnancy, children, drug interaction
- Person-centered approach, DOT
- Other options for tuberculosis treatment
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Zellweger, J. (2021, September 29). Treatment of tuberculosis [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/FULV5792.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Jean-Pierre Zellweger has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Respiratory Diseases
Transcript
Please wait while the transcript is being prepared...
0:00
Hello everybody, welcome to this webinar session.
My name is Jean-Pierre Zellweger, I am a Swiss pulmonary physician,
former chief of the TB clinic at the University Hospital in Lausanne,
now retired and working part-time as a consultant for
the TB Competence Centre of the Swiss Lung Association in Bern, Switzerland.
0:24
I have no conflict of interest for this presentation, and as a clinician
I will present the issue of TB treatment from a clinical point of view,
which may sometimes be oversimplified.
0:38
The content of my presentation will speak about: the history of chemotherapy;
present the current first-line drugs and mechanisms of action;
some of the main second-line drugs;
the standard regimens;
I will address some special situations like pregnancy, children, or CNS tuberculosis;
I will speak about the person-centred approach and directly observed therapy;
and mention, at the end, some other options for TB treatment.
1:09
The history of chemotherapy of tuberculosis is ancient, but for some authors like Laennec,
the cure of phthisis (which is tuberculosis) is possible for nature, but it's not for medicine.
Laennec considered all remedies proposed for the treatment of TB as inefficient, which was actually true in 1819.
For Robert Koch, after the failure of tuberculin trials,
prevention and vaccination were the only prospect for a cure of TB.
My predecessor at the TB dispensary in Lausanne declared - in 1940 - that,
"We are not here for healing TB", but this was before the advent of chemotherapy.
All attempts at the medical treatment of tuberculosis by calcium, gold salts,
sulfonamides and others, failed until the discovery and use of streptomycin in 1946.